A Critical Role for the Transient Receptor Potential Channel Type 6 in Human Platelet Activation

Hari Priya Vemana*, Zubair A. Karim*, Christine Conlon, Fadi T. Khasawneh*

Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America

* These authors contributed equally to this work.
* fkhasawneh@westernu.edu

Abstract

While calcium signaling is known to play vital roles in platelet function, the mechanisms underlying its receptor-operated calcium entry component (ROCE) remain poorly understood. It has been proposed, but never proven in platelets, that the canonical transient receptor potential channel-6 (TRPC6) mediates ROCE. Nonetheless, we have previously shown that the mouse TRPC6 regulates hemostasis, thrombogenesis by regulating platelet aggregation. In the present studies, we used a pharmacological approach to characterize the role of TRPC6 in human platelet biology. Thus, interestingly, we observed that a TRPC6 inhibitor exerted significant inhibitory effects on human platelet aggregation in a thromboxane receptor (TPR)-selective manner; no additional inhibition was observed in the presence of the calcium chelator BAPTA. This inhibitor also significantly inhibited human platelet secretion (dense and alpha granules), integrin IIb-IIIa, Akt and ERK phosphorylation, again, in a TPR-selective manner; no effects were observed in response to ADP receptor stimulation. Furthermore, there was a causal relationship between these inhibitory effects, and the capacity of the TRPC6 inhibitor to abrogate elevation in intracellular calcium, that was again found to be TPR-specific. This effect was not found to be due to antagonism of TPR, as the TRPC6 inhibitor did not displace the radiolabeled antagonist [3H]SQ29,548 from its binding sites. Finally, our studies also revealed that TRPC6 regulates human clot retraction, as well as physiological hemostasis and thrombus formation, in mice. Taken together, our findings demonstrate, for the first time, that TRPC6 directly regulates TPR-dependent ROCE and platelet function. Moreover, these data highlight TRPC6 as a novel promising therapeutic strategy for managing thrombotic disorders.

Introduction

Platelets are anucleate cells that play an important role in hemostasis and thrombosis [1]. With regards to platelet activating agents, thromboxane A2 (TXA2) is one of the most studied platelet...
agonists. Studies on platelets demonstrated that TXA2 signals, at least in part, through the regulation of cellular calcium upon binding to its G Protein Coupled Receptor (GPCR), i.e., known as the thromboxane receptor (TPR). It is now clear that TPR controls additional aspects of cellular function, specifically through coupling to multiple G-proteins (GPs) including Gq, G13, and G11. Nonetheless, functional and physical coupling of platelet TPRs has only been documented with two GPs, i.e., Gq and G13, with the Gq-PLCβ-inositol triphosphate (IP3)-Ca2+-signaling cascade being the most characterized of the two.

In this regard, experiments by Offermanns group have provided evidence that platelet shape change can be stimulated through G12/13 pathway. Specifically, it was shown that TPR-mediated platelet shape change was still observed in mice deficient in Gq, whereas the aggregation response was lacking. This suggestion would seem to be consistent with earlier observations that TPR agonists can induce platelet shape change in the absence of measurable intracellular calcium levels (which is presumably a Gq-mediated event). Changes in intracellular calcium have been shown to play essential roles in the initial activation of platelets and the recruitment of feedback signaling mechanisms such as ADP secretion. In turn, these feedback mechanisms (ADP) will initiate separate GPCR-signaling in platelets that also involve calcium entry. While research efforts have attempted to define the channels involved in the Gq-dependent, receptor-operated calcium entry (ROCE) and store-operated calcium entry (SOCE), studies on the expression profile of TRPCs in platelets indicate that platelets express low levels of TRPC1 that is mostly found in the intracellular membrane, and high levels of TRPC6 that is exclusively found in the plasma membrane. Regarding the role of TRPC1 in platelet function, experiments using the TRPC1 knockout (KO) platelets revealed that these platelets displayed fully intact SOCE, unaltered calcium homeostasis, and intact in vitro and in vivo platelet function. Based on these considerations, clearly the role of TRPC6 in platelet function warrants investigation. To this end, our own findings using TRPC6 KO mice have shown that TRPC6 plays a critical role in physiological hemostasis and thrombogenesis. These defects were attributed to defective platelet aggregation, downstream of TPR. However, whether TRPC6 regulates ROCE, and plays a critical role in human platelet function remains unknown. To a large extent, this derived, from lack of pharmacological tools or inhibitors to study the role of TRPC6 channels in human platelets. Thus, our current work utilized a new TRPC6 inhibitor to characterize its role in platelet function. Our findings demonstrated, for the first time, that TRPC6 mediates ROCE, thereby regulating platelet aggregation, secretion, integrin exposure, as well as Akt and ERK phosphorylation, and that, interestingly, it does so in a TPR-dependent/selective manner. Importantly, these effects did not derive from TPR antagonism by the TRPC6 inhibitor, as the latter could not displace the antagonist [3H]SQ29,548 from its TPR binding sites. Of note, when the TRPC6 inhibitor was combined with BAPTA, the calcium chelator, no additional inhibition of aggregation was observed beyond that observed with BAPTA alone, i.e., its inhibitory effects could no longer be observed. Finally, we also found that TRPC6 is involved in clot retraction and contributes to hemostasis and thrombosis.

Materials and Methods

Human blood studies were approved by the Institutional Review Board (IRB) at Western University of Health Sciences, Pomona, CA, and donors were asked to sign a written consent, and a subjects’ bill of rights, that were previously approved by the IRB.
Reagents

U46619 was from Cayman Chemical (Ann Arbor, MI). Thrombin receptor activating peptide 4 (TRAP4; AYPGKF-NH2) and ADP analog Adenosine 5'-[β-thio]diphosphate trilithium salt was from Sigma Aldrich (St. Louis, MO). Antibodies for Akt, pAkt, ERK and pERK were from Cell Signaling (Danvers, MA). ADP and other platelet disposables were from Chrono-Log (Havertown, PA). TRPC6 inhibitor (GsMTx-4) was from Alomone labs (Israel). FITC-conjugated Annexin V, anti–P-selectin, and PAC-1 antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA). Fura-2 acetoxyethyl ester (fura-2/AM) and Pluronic F-127 were from Invitrogen (Grand Island, NY). Sodium citrate, whatman filter paper, ferric chloride, sodium chloride, potassium chloride, sodium dihydrogen phosphate, magnesium chloride, sodium bicarbonate, and D-dextrose were from Fisher Scientific (Hanover Park, IL). The radiolabeled [3H]SQ29,548 was purchased from PerkinElmer (Waltham, MA). BAPTA was purchased from Tocris Bioscience (Ellisville, Missouri). The C57BL/6 mice were obtained from Jackson laboratory (Bar Harbor, ME). Platelet count was determined using an automated hematology analyzer (Drew Scientific Dallas, TX).

Animals

C57BL/6 J mice were from Jackson Laboratories (Bar Harbor, ME). All mice used for experiments were 8–10 weeks of age. All experiments involving animals were performed in compliance with the relevant laws and institutional guidelines, and were approved by the Western University of Health Sciences Institutional Animal Care and Use Committee.

Preparation of Human Platelets

Blood was drawn from healthy volunteers who denied taking any medication for 1 week prior to collection. Coagulation was inhibited by 3.8% w/v sodium citrate solution (1 part sodium citrate to 9 parts blood). Human platelet rich plasma (PRP) was obtained by centrifugation at room temperature. Platelets were counted with automated hematology analyzer and their count was adjusted to 7 x 10⁷ platelets/ml, prior to each experiment. Washed human platelets were prepared as we described [33]. PRP was isolated in the presence of 0.37 U/ml apyrase and 10 ng/ml PGI₁, by centrifugation at 150 × g for 10 min at 20°C. PRP was centrifuged at 900 × g for 10 min and pelleted platelets were resuspended in HEPES/Tyrode’s buffer (20 mM HEPES/NaOH, pH 6.5, 128 mM NaCl, 2.8 mM KCl, 1 mM MgCl₂, 5 mM D-glucose, 12 mM NaHCO₃, 0.4 mM NaH₂PO₄) containing 1 mM EGTA, 0.37 U/ml apyrase, and 10 ng/ml PGI₂. Platelets were washed and resuspended in HEPES/Tyrode’s buffer (pH 7.4) without EGTA, apyrase, or PGI₁. The final platelet count was adjusted to 4 × 10⁸ platelets/ml, unless otherwise indicated. PRP was isolated in the presence of apyrase (0.37 U/ml) and PGI₁ (10 ng/ml) by centrifugation at 150 × g for 10 min at RT. PRP was centrifuged at 900 × g for 10 min and platelets were resuspended in HEPES/Tyrode’s buffer containing 1 mM EGTA, apyrase, and PGI₂. Platelets were washed and resuspended in HEPES/Tyrode’s buffer (pH 7.4) without EGTA, apyrase, or PGI₂.

In vitro Platelet Aggregation and Secretion

PRP was incubated with TRPC6 inhibitor (10 μM) for 5 min prior to experiments, except in control experiments. Platelets were activated with ADP (5 μM) and U46619 (0.5 μM) in the presence or absence of TRPC6 inhibitor (10 μM). Platelets were also activated with U46619 (0.5 μM) in the presence and absence of the TRPC6 inhibitor (10 μM) with or without the addition of BAPTA (10 μM). Platelet aggregation was measured by the turbidometric method using model 490 aggregometer (Chrono-Log Corporation, Havertown, PA). ATP secretion was
monitored in parallel with platelet aggregation after addition of the luciferin-luciferase (1% [v/v] final concentration) reagent to the same PRP suspension used for aggregation and measured for ATP secretion upon adding 1 μM U46619 and 0.1 U/ml thrombin. Each experiment was repeated at least 3 times, with blood collected from three different human donors.

**Flow Cytometric Analysis**

Flow cytometric analysis was carried out as we described [34]. Human platelets (2 × 10⁸) were incubated in the presence or absence of TRPC6 inhibitor (10 μM) for 5 minutes and then stimulated with thrombin (0.1 U/ml), U46619 (0.5 μM) for 3 minutes. The reactions were stopped by fixing the platelets with 2% formaldehyde for 30 min at room temperature. Platelets were incubated with FITC-conjugated anti–P-selectin or PAC-1 antibodies at room temperature for 30 min in the dark. Finally, the platelets were diluted 2.5 fold with HEPES/Tyrode buffer (pH 7.4). The samples were transferred to FACS-tubes and fluorescent intensities were measured using a BD Accuri C6 flow cytometer and analyzed using CFlow Plus (BD Biosciences, Franklin Lakes, NJ).

**Measurement of Intracellular Calcium in Platelets**

Intra-platelet calcium was measured using Fura-2-acetoxymethyl ester (Fura-2AM) as described [33]. Human platelets (2.0 x 10⁸/ml) were labeled with 12.5 μM Fura-2AM and 0.2% Pluronic F-127 in HEPES/Tyrode buffer (pH 7.4) for 45 min at 37°C. After washing, the platelets were resuspended without apyrase to a concentration of 2.0 x 10⁸/ml. Samples (1 ml) were added to siliconized cuvettes, recalcified with 0.7 mM CaCl₂, and incubated in the presence or absence of TRPC6 inhibitor (10 μM) for 5 min and then stimulated with OAG (150 μM) for 3 min with constant stirring. Fluorescence was analyzed by excitation at 340 nm and 380 nm and emission was measured at 509 nm using a model LS50B Luminescence Spectrometer (Perkin-Elmer Instruments, Shelton, CT). The ratio of fura-2 emissions were calculated simultaneously using FL WinLab software and converted to [Ca²⁺]ᵢ as described previously [35].

**Immunoblotting**

Immunoblotting was carried out as described [33]. Briefly, human platelets were incubated in the presence or absence of TRPC6 inhibitor (10 μM) for 5 minutes and then stimulated with U46619 (0.5 μM) and ADP•β•S (100 μM) for 3 minutes followed by lysis with 1 × lysis buffer. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immobilon-P PVDF membranes (Bio-Rad, Hercules, CA). They were then probed with the primary antibodies (ERK, pERK, Akt and pAkt) and visualized with horseradish peroxidase-labeled anti-rabbit or anti-mouse IgG as required. The antibody binding was detected using enhanced chemiluminescence substrate (Thermo Scientific, Rockford, IL). Images were obtained with ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA) and quantified with Image Lab software Version 4.1 (Bio-Rad, Hercules, CA).

**Fibrin Clot Retraction Assay**

With slight modification fibrin clot retraction assay was performed as discussed in Osdoit and Rosa [36]. Briefly, whole blood was collected and washed platelets were isolated as discussed above. CaCl₂ was added extemporaneously, at a final concentration of 1 mM. Glass tubes designed for aggregation were used for retraction assays. First, a 10% (w/v) polycrylamide cushion was polymerized at the bottom of the tubes to avoid clot adherence. Tubes were then rinsed extensively in distilled water. Washed platelets resuspended at 1×10⁸/ml in Hepes-
Tyrode buffer (pH 7.4). Platelets were incubated with TRPC6 inhibitor (10 μM) for 5 min. Fibrinogen (500 μg/ml) was added in 0.5 ml platelets aliquots, and clot retraction was initiated by quickly adding thrombin (0.1 U/ml). The reaction was transferred to the glass tube and the reaction was set at room temperature. Pictures were taken at time intervals of 10 min up to one hour using a digital camera.

**Binding Assay**

These experiments were conducted as we described before [37]. Resuspended platelets were prepared as we described previously [38]. The platelet suspension (1 x10^9 platelets/ml) was incubated with the radiolabeled [3H]SQ29,548 (1 nM) at RT for 10 min, and then increasing concentrations of the displacing TRPC6 inhibitor (10–50 μM) were added for an additional 45 min. The [3H]SQ29,548 bound platelets were captured by running through 0.45 mm Millipore filter over a vacuum suction unit. The filters were then washed once and counted for radioactivity in a Beckman LS 6000 liquid scintillation counter.

**Tail bleeding time assay**

Mice 8–10 weeks old were injected with and without TRPC6 inhibitor and the bleeding time was recorded one-hour post injection. Hemostasis was measured using the tail transection technique [34]. Briefly, mice were anesthetized using isoflurane and then placed on a 37°C heating blanket (Harvard Apparatus Limited, Edenbridge, KY, USA) before the tail was transected with a clean cut using a sterile scalpel at a distance of 5 mm from the tip. After transection, the tail was immediately immersed in saline maintained at 37°C, constant temperature. Bleeding was observed visually and recorded as the time from the tail transection to the moment the blood flow stopped and did not resume within 60 s from the initial cessation time. Normal bleeding times for murine specimens lasts between 1–3 min. However, when bleeding did not stop within 15 min, pressure was applied to the tail and styptic powder was used to help close the wound, thus avoiding excessive loss of blood. Bleeding times beyond 15 min were considered as the cut-off time for the purpose of statistical analysis.

**In vivo thrombosis model**

These studies were performed as described previously [34, 39]. Mice that are 8–10 weeks old were injected with and without TRPC6 inhibitor. Animals were anesthetized and placed on a 37°C heated surgical table under a stereo microscope (Leica Microsystems Ltd, CH-9435, Heerbrugg, Switzerland). A midline incision of the skin was made directly on top of the right common carotid artery region, and a segment of the left common carotid artery was exposed and cleaned. Baseline carotid blood flow was measured and recorded with a miniature Doppler flow probe (Model 0.5 VB, Transonic System, Ithaca, NY, US), interfaced with a flowmeter (model TS402, Transonic Systems). Thrombosis was induced by applying a saturated segment of filter paper (0.5 × 1 mm) in 7.5% ferric chloride, onto the carotid artery. After 3 min of exposure, the filter paper was removed. The carotid blood flow was continuously monitored for 45 min after ferric chloride application, and the data was registered by a computerized data acquisition program (LabChart6, ADInstruments, Colorado Springs, CO, and USA). Time to occlusion was calculated as the difference in time between the removal of the filter paper and stable occlusion, which was described as zero blood flow for 2 min. An occlusion time beyond 45 min was considered as the cut-off time for the purpose of statistical analysis.
Statistical Analysis

All experiments were performed at least three times. Analysis of the data was performed using GraphPad PRISM statistical software (San Diego, CA) and presented as mean ± SEM. The Mann-Whitney test was used for the evaluation of differences in mean occlusion and bleeding times. Analysis was also conducted using t-test, and similar results were obtained. Significance was accepted at P < 0.05 (two-tailed P value), unless stated otherwise.

Results

Effect of TRPC6 inhibitor on platelet Aggregation

In order to evaluate the role of the TRPC6 in platelet function downstream of TPRs and other Gq-coupled receptors, TRPC6 inhibitor (pharmacological approach) was employed in our studies. Our initial experiments revealed that the 5 μM of the TRPC6 inhibitor exerted significant inhibitory effect on platelet aggregation induced by 0.5 μM of the TPR agonist U46619, when compared to vehicle control (Fig 1). This inhibitory effect was found to be dose (10 μM) dependent (Fig 1). This is the first demonstration that the mechanism by which TPRs stimulate platelet aggregation involves TRPC6. On the other hand, there was no difference in the aggregation response between TRPC6 inhibitor-, and control-treated platelets when they are stimulated by either 5 μM ADP or 60 μM of TRAP4 (Fig 1). These results indicate that the inhibition of aggregation in the presence of the TRPC6 inhibitor is agonist/receptor (i.e., TPR)-specific.

Fig 1. Effect of TRPC6 inhibitor on human platelet aggregation. PRP was incubated without or with the TRPC6 inhibitor (5 μM and/or 10 μM) for 5 min followed by stimulation with (A) U46619 (0.5 μM), (B) ADP (5 μM), (C) TRAP4 (60 μM), or (D) U46619 (0.5 μM) with or without BAPTA (10 μM). Each experiment was repeated three times, with three separate donors.

doi:10.1371/journal.pone.0125764.g001
In addition, to assess the specificity of TRPC6 inhibitor we first treated with BAPTA to chelate extracellular calcium. As one might expect, when the TRPC6 inhibitor was combined with BAPTA, no additional inhibition of aggregation was detected beyond that observed with BAPTA alone (Fig 1), i.e., its inhibitory effects could no longer be observed. This finding is consistent with the notion that TRPC6 mediates calcium entry and further argues for the specificity of this inhibitor.

Next, we sought to investigate whether the inhibition of aggregation, would be accompanied by inhibition of GPIIb-IIIa activation. Indeed, we observed significant blockade of U46619 (0.5 μM)-induced activation of GPIIb-IIIa, in (10 μM) TRPC6 inhibitor-treated platelets, compared to control (Fig 2). Conversely, we did not detect any inhibition in GPIIb-IIIa in response to 5 μM of the agonist ADP (Fig 2).

Effect of TRPC6 inhibitor on platelet dense and alpha granule secretion

We next assessed the effect of the TRPC6 inhibitor on platelet secretion (dense and alpha granules). It was found that 0.5 μM U46619-induced ATP release, a measure of dense granule secretion, was inhibited when the platelets were incubated with 10 μM of the TRPC6 inhibitor (Fig 3). The U46619-triggered alpha granule secretion analyzed by flow cytometry of P-selectin also was inhibited in platelets treated with TRPC6 inhibitor (Fig 4). In contrast, and as one might expect in light of the aggregation and GPIIb-IIIa data, the TRPC6 inhibitor did not exert any apparent inhibitory effects on 5 μM ADP-induced dense and alpha granule secretion (Fig 3).
This data combined with the GPIIb-IIIa activation indicate that TRPC6 inhibitor has the capacity to inhibit expression of multiple markers of platelet activation.

Fig 3. Effect of TRPC6 inhibitor on human platelet ATP secretion stimulated by U46619. PRP was incubated without or with TRPC6 inhibitor (10 μM) for 5 min followed by stimulation of PRP with (A) U46619 (0.5 μM), or (B) ADP (5 μM). Each experiment was repeated three times, with three separate donors.

doi:10.1371/journal.pone.0125764.g003

and Fig 4. This data combined with the GPIIb-IIIa activation indicate that TRPC6 inhibitor has the capacity to inhibit expression of multiple markers of platelet activation.

Fig 4. Effect of TRPC6 inhibitor on alpha granule secretion (P-selectin expression). Washed platelets were incubated in the presence or absence of TRPC6 inhibitor (10 μM) for 5 minutes and then stimulated with U46619 (0.5 μM) and ADP (5 μM) for 3 minutes. The reactions were stopped by fixing the platelets with 2% formaldehyde for 30 min at room temperature. Platelets were incubated with FITC-conjugated anti–P-selectin antibody, the fluorescent intensities were measured by flow cytometry, and the data were plotted as histogram. Each experiment was repeated at least four times, with blood obtained from four separate donors (P < 0.01, Mann-Whitney test).

doi:10.1371/journal.pone.0125764.g004
Effect of TRPC6 inhibitor on intracellular calcium

In this set of experiments we investigated the role of TRPC6 in ROCE, in order to confirm that the aforementioned “defects” in platelet function are causally related to inhibition of calcium homeostasis/entry by the TRPC6 inhibitor. As expected, the TRPC6 inhibitor (10 μM) significantly lowered intracellular calcium level in response to the TPR agonist U46619 (0.5 μM; Fig 5A), but was without any apparent effects when platelets were stimulated by 100 μM of the stable ADP analog Adenosine 5’-[β-thio] diphosphate trilithium salt (ADPβS; Fig 5A). To further confirm these findings, we next utilized a membrane permeable analogue of the Gq activator diacylglycerol (DAG), namely 1-oleoyl-2-acetyl-sn-glycerol (OAG), which is previously shown to be an agonist for TRPC6. Our measurements revealed that TRPC6 inhibitor (10 μM) produced significant inhibition on 150 μM OAG-induced ROCE, when compared to the control (Fig 5A). To biochemically confirm our findings; we next examined the effect of the TRPC6 inhibitor on ERK and Akt phosphorylation, which are known to be downstream of TPRs. It was found that incubation with 10 μM of the TRPC6 inhibitor, ameliorated phosphorylation of ERK and Akt upon stimulation with 0.5 μM U46619, but not with ADPβS (Fig 5B).

Effect of the TRPC6 inhibitor on binding of the radiolabelled TPR antagonist [3H]SQ29,548

In order to further define the molecular mechanism by which the TRPC6 inhibitor exerts its inhibitory effects on platelets, a displacement radiolabeled ligand binding assay was performed. Thus, platelets were incubated with the radiolabeled TPR antagonist [3H]SQ29,548, and increasing concentrations of TRPC6 inhibitor (10–50 μM) were added. The TRPC6 inhibitor, at a concentration that almost completely inhibited aggregation (10 μM; Fig 6) did not appear to displace [3H]SQ29,548 from its TPR binding sites. In fact, no ligand displacement was observed even with a TRPC6 inhibitor concentration as high as 50 μM (Fig 6). These findings indicate that the mechanism by which TRPC6 inhibitor exerts its effects on platelets does not involve TPR antagonism.

Effect of TRPC6 inhibitor on clot retraction

To test the possibility that TRPC6 may regulate the ability of platelets to generate contractile forces, we analyzed the effect of the TRPC6 inhibitor on clot retraction. Indeed, it was found that the TRPC6 inhibitor (10 μM) significantly inhibited clot retraction, when compared with
the control (Fig 7), indicating that TRPC6 affects does play a role in integrin outside-in signaling [40, 41].

Effect of TRPC6 inhibitor on hemostasis

Given the established role of Ca^{2+} signaling in platelet biology, and our present findings that TRPC6 regulates (TPR-mediated) in vitro platelet function, we next investigated whether ROCE/TRPC6 is involved in hemostasis (i.e., in vivo platelet function). Our studies revealed that mice injected with 10 μM of the TRPC6 inhibitor exhibited a significantly prolonged tail bleeding time, in comparison to the mice injected with vehicle control (Fig 8A).

Effect of TRPC6 inhibitor on clot retraction

Clot retraction of washed platelets was initiated by adding thrombin (0.1 U/ml) in the presence or absence of TRPC6 inhibitor (10 μM) and photographed for every 10 minutes up to one hour (n = 4).

---

Fig 6. Effect of the TRPC6 inhibitor on binding of the radiolabelled TPR antagonist [3H]SQ29,548. Binding displacement of 1 nM [3H]SQ29,548 with increasing concentrations of the TRPC6 inhibitor (10–50 μM), in human platelets (n = 3; P < 0.01, Mann-Whitney test).

doi:10.1371/journal.pone.0125764.g006

Fig 7. Effect of TRPC6 inhibitor on clot retraction. Clot retraction of washed platelets was initiated by adding thrombin (0.1 U/ml) in the presence or absence of TRPC6 inhibitor (10 μM) and photographed for every 10 minutes up to one hour (n = 4).

doi:10.1371/journal.pone.0125764.g007
Effect of TRPC6 inhibitor on thrombus formation

In the last set of studies, we examined the contribution of TRPC6 to thrombogenesis, using a FeCl₃-induced carotid artery thrombosis model. As might be expected given the role of TPRs in thrombus formation, mice treated with the TRPC6 inhibitor (10 μM) exhibited a significantly prolonged time for occlusion, when compared with the control (Fig 8B). Therefore, this finding indicates that the TRPC6 inhibitor protects against the development of thrombotic events in vivo, supporting the notion that TRPC6 contributes to thrombotic disease states.

Discussion

Although calcium signaling has been shown to play an important role in platelet function, the molecular mechanism underlying its receptor-operated component (i.e., ROCE) is still poorly understood. It has been proposed, though never proven, that transient receptor potential channels participate in ROCE and are therefore directly involved in platelet activation. Since calcium signaling plays an important role in in vivo platelet activation and thrombus formation and given that most if not all agonists signal through regulation of cellular calcium, investigating the role of TRPC6 in TPR, and other Gq-coupled receptors, such as ADP (i.e., P2Y₁) and PAR4, seems clearly warranted. We have previously shown using a genetic deletion approach in mice, that the mouse TRPC6 regulates platelet aggregation, and is involved in hemostasis and thrombogenesis [32]. However, whether TRPC6 plays a role in human platelet function, species-specific differences, remains to be investigated. To this end, in human platelets, TRPC6 has been reported to be highly expressed as compared to other TRPC isoforms. Based on these considerations, we propose that TRPC6 plays an important role in intracellular-calcium changes (ROCE) and platelet activation, downstream of TPRs and other Gq-coupled receptors. In order to address this issue, we employed a pharmacological inhibitor of TRPC6. Thus, we found that the TRPC6 inhibitor treated platelets exhibited an impaired aggregation, GPIIb-IIIa activation, dense and alpha granule secretion, in response to TPR agonist stimulation. However, there was no apparent difference between TRPC6 inhibitor, and control-treated platelets, when stimulated by ADP (or TRAP4). These findings support the notion, that TPR-mediated human platelet function is dependent on TRPC6, and that the latter’s role in platelets is receptor/agonist specific. Of note, the defect in TPR-mediated aggregation is consistent with that we observed in TRPC6 KO mice ([32]; and unpublished findings). Also, no further inhibition of aggregation was observed when platelets were treated with BAPTA and TRPC6 inhibitor when compared to BAPTA alone. This finding supports the specificity of the TRPC6 inhibitor; suggests that BAPTA chelated extracellular calcium including that which would have otherwise/
presumably entered through TRPC6; and is consistent with the notion that TRPC6 does mediate calcium entry. We next sought to further define the role of TRPC6 in ROCE, as well as determine whether the aforementioned inhibitory effects on platelet function observed with the TRPC6 inhibitor are causally related to a blockade of ROCE. Indeed, it was found that the Gq agonist/TRPC6 activator [42] OAG stimulated ROCE, and that treatment with the TRPC6 inhibitor resulted in significant attenuation of ROCE. This is the first demonstration that TRPC6 regulates ROCE in human platelets, and indicate that there is a causal relationship between calcium homeostasis/entry and the inhibition of the various TPR-mediated platelet functional responses by the TRPC6 inhibitor. The fact that TRPC6 appears to play a selective role in TPR-mediated platelet function is rather a peculiar/interesting phenotype. This observation could be explained, in large, on the basis of the importance of Gq-coupling to the individual receptors studied. Thus, given that TRPC6 is thought to be downstream of Gq, it is expected that signaling pathways that are heavily dependent/reliant on Gq would be affected in presence of TRPC6 inhibitor. As for TPRs, work by Offermanns’ group have provided evidence that platelet shape change can be stimulated through the G12/13 pathway [18, 20], whereas aggregation and other responses are Gq-mediated; which supports the notion that the latter is the primary pathway. On the other hand, there is substantial evidence that ADP and PAR signaling [43] are heavily dependent on G1 and G13, respectively. This is based on studies (using Gq knockout (KO) mice), in which it was concluded that PAR-mediated co-activation of G12/13 and G13-mediated signaling pathways is sufficient to induce platelet activation [26], and that G13 downstream of PAR has the capacity to increase intracellular calcium [44–46]. It is also possible that TRPC6/ROCE role in the various platelet functional responses may have an underlying temporal basis or be regulated via compartmentalization-dependent mechanisms; support of the latter hypothesis derives from previous studies that reported that functional compartmentalization of intracellular calcium with TRPC6 in particular does indeed exist [47, 48]. Having established the role of TRPC6 using “functional” assays, we next sought to confirm our findings biochemically by studying ERK and Akt phosphorylation. Indeed, our biochemical results revealed that TRPC6 regulates TPR-mediated activation of ERK and Akt, which is consistent with the platelet functional experiments, and the role of ERK and Akt in TPR signaling [49–51]. Of note, the “TPR-selective” phenotype observed supports the notion that the TRPC6 inhibitor is rather specific. To further investigate the mechanism of action of TRPC6 inhibitor, and exclude the possibility that it is acting as an antagonist for TPR, radioligand displacement binding studies were performed. Our results revealed that the TRPC6 inhibitor could not displace [3H] SQ29,548 from the platelet TPR binding sites, even when used at a concentration as high as five-fold of that that almost completely inhibited the aggregation response; which is consistent with it being an inhibitor for TRPC6 itself.

We next examined if TRPC6/ROCE regulates fibrin clot retraction, and found that TRPC6 inhibitor does indeed inhibit clot retraction. This data suggests that TRPC6 is involved in outside-in signaling. Finally, having established the capacity of TRPC6 to play a critical role in platelet function (in vitro) and in clot retraction, we next determined whether these effects would uphold under in vivo experimental models (e.g., antithrombotic activity). Hence, the mice were injected with TRPC6 inhibitor and subjected to the tail bleeding time assay. We found that inhibitor-treated mice exhibited impaired hemostasis as shown by their significantly prolonged bleeding times. The impaired hemostasis in these mice can be attributed to the defective TPR function, in the presence of the TRPC6 inhibitor. Given that it is well documented that calcium signaling plays an important role in the development of occlusive disorders, we sought to examine with its receptor-operated component via TRPC6 participates in thrombogenesis. Indeed, our data revealed that treatment with its inhibitor prolonged the time for occlusion, indicating that TRPC6 contributes to thrombus formation. This finding supports the
notion that TRPC6 could be a target for novel anti-thrombotic agents, and is consistent with our previous findings [32] in which we showed that TRPC6 deletion in mice impairs hemostasis and thrombosis, as well as platelet aggregation in response activation by TRPs. To this end, a separate study showed that platelet functional responses were not affected by TRPC6 deletion in mice [52]. The differences between their findings and our human data with regards to platelet functional responses can be attributed to the different species and different experimental conditions. As for the differences in the in vivo phenotype, they are likely to be due to the experimental conditions, doses of agonist, genetic background, as well as the age of the animals used in these studies [53]. The latter issue is rather intriguing given that the role of TRPC6 has been indeed found to developmental stage dependent [53], something we were able to document in our laboratory (unpublished findings). Of note, our published mouse TRPC6 data [32] argues against species as an attributing factor since we observed that TRPC6 KO mice platelets exhibited a defect in their platelet functional responses.

Taken together, these data demonstrate that the mechanism by which TPR-mediates platelet aggregation, integrin activation, and secretion involves TRPC6 dependent CE. Furthermore, TRPC6 also regulates clot retraction, plays a physiologically relevant role in normal hemostasis, and in the pathogenesis of occlusive thrombi. We are the first to document the direct role of TRPC6 and ROCE in human platelets. Finally, our studies may define TRPC6 as a novel therapeutic target for managing multiple thrombosis-based disorders, albeit it may be associated with bleeding limitations, similar to all clinical antiplatelet agents.

Acknowledgments

This research was supported by funds provided by The American Heart Association, Grant Number 14GRNT20450127 (to F.T.K). This work has been approved by Institutional Review Board and the Institutional Animal Care and Use Committee at Western University of Health Sciences, as applicable.

Author Contributions

Conceived and designed the experiments: FTK ZAK. Performed the experiments: HPV ZAK CC. Analyzed the data: HPV ZAK FTK CC. Contributed reagents/materials/analysis tools: HPV ZAK CC FTK. Wrote the paper: HPV ZAK FTK.

References

1. Behnke O (1970) Microtubules in disk-shaped blood cells. Int Rev Exp Pathol 9: 1–92. PMID: 5499012
2. Parise LV, Venton DL, Le Breton GC (1984) Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction. J Pharmacol Exp Ther 228: 240–244. PMID: 6319669
3. Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 72: 2994–2998. PMID: 1059088
4. Ghali NI, Kattelman EJ, Hung SC, Schnorf KE, Le Breton GC, Venton DL. (1984) Synthesis of [17,18-3H] trans-13-azaprostanoic acid. A labeled probe for the PGH2/TXA2 receptor. Prostaglandins 27: 865–876. PMID: 6091182
5. Hung SC, Ghali NI, Venton DL, Le Breton GC (1983) Specific binding of the thromboxane A2 antagonist 13-azaprostanoic acid to human platelet membranes. Biochim Biophys Acta 728: 171–178. PMID: 6219702
6. Halushka PV, Mais DE, Mayeux PR, Morinelli TA (1989) Thromboxane, prostaglandin and leukotriene receptors. Annu Rev Pharmacol Toxicol 29: 213–239. PMID: 2543270
7. Owen NE, Le Breton GC (1981) Ca2+ mobilization in blood platelets as visualized by chlortetracycline fluorescence. Am J Physiol 241: H613–619. PMID: 6274207
8. Knezevic I, Borg C, Le Breton GC (1993) Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2/prostaglandin H2 receptors. The Journal of biological chemistry 268: 26011–26017. PMID: 8245033

9. Shenker A, Goldsmith P, Unson CG, Spiegel AM (1991) The G protein coupled to the thromboxane A2 receptor in human platelets is a member of the novel Gq family. The Journal of biological chemistry 266: 9309–9313. PMID: 1851174

10. Kinsella BT, O'Mahony DJ, Fitzgerald GA (1997) The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther 281: 957–964. PMID: 9152406

11. Djellas Y, Manganello JM, Antonakis K, Le Breton GC (1999) Identification of Galpha13 as one of the G-proteins that couple to human platelet thromboxane A2 receptors. The Journal of biological chemistry 274: 14325–14330. PMID: 10318854

12. Offermanns S, Hu YH, Simon MI (1996) Galpha12 and galpha13 are phosphorylated during platelet activation. The Journal of biological chemistry 271: 26044–26048. PMID: 8824244

13. Offermanns S, Laugwitz KL, Spicher K, Schultz G (1994) G proteins of the G12 family are activated via Ushikubi F, Nakamura K, Narumiya S (1994) Functional reconstitution of platelet thromboxane A2 receptor with Gq and G2i in phospholipid vesicles. Mol Pharmacol 46: 808–816. PMID: 7969066

15. Gao Y, Tang S, Zhou S, Ware JA (2001) The thromboxane A2 receptor activates mitogen-activated protein kinase via protein kinase C-dependent Gi coupling and Src-dependent phosphorylation of the epidermal growth factor receptor. J Pharmacol Exp Ther 296: 426–433. PMID: 11160627

16. Brass LF, Manning DR, Cichowski K, Abrams CS (1997) Signaling through G proteins in platelets: to the integrins and beyond. Thrombosis and haemostasis 78: 581–589. PMID: 9198220

17. Yang J, Wu J, Kowalska MA, Dalvi A, Prevost N, O'Brien PJ, et al (2000) Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci U S A 97: 9984–9989. PMID: 10954748

18. Klages B, Brandt U, Simon MI, Offermanns S (1999) Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 144: 745–754. PMID: 10037795

19. Singh I, Knezevic N, Ahmmed GU, Kini V, Malik AB, Mehta D (2007) Galphaq-TRPC6-mediated Ca2+ entry induces RhoA activation and resultant endothelial cell shape change in response to thrombin. The Journal of biological chemistry 282: 7833–7843. PMID: 17197445

20. Offermanns S, Toombs CF, Hu YH and Simon MI (1997) Defective platelet activation in G alpha(q)-deficient mice. Nature 389: 183–186. PMID: 9296496

21. Bauer M, Retzer M, Wilde JI, Maschberger P, Essler M, Watson SP, et al. (1999) Dichotomous regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets. Blood 94: 1665–1672. PMID: 10477691

22. Authi KS (1993) Ca2+ homeostasis and intracellular pools in human platelets. Adv Exp Med Biol 344: 83–104. PMID: 8209795

23. Quinton TM, Kim S, Dangelmaier C, Dorsam RT, Jin J, Daniel JL, et al. (2002) Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation. Biochem J 368: 535–543. PMID: 12215172

24. Yang X, Sun L, Gabbeta J, Rao AK (1997) Platelet activation with combination of ionophore A23187 and a direct protein kinase C activator induces normal secretion in patients with impaired receptor mediated secretion and abnormal signal transduction. Thrombosis research 88: 317–327. PMID: 9526952

25. Charo IF, Feinman RD, Detwiler TC (1977) Interrelations of platelet aggregation and secretion. The Journal of clinical investigation 60: 866–873. PMID: 330568

26. Nesbitt WS, Giuliano S, Kulkami S, Dopheide SM, Harper IS, Jackson SP (2003) Intercellular calcium communication regulates platelet aggregation and thrombus growth. J Cell Biol 160: 1151–1161. PMID: 12668663

27. Liao Y, Plummer NW, George MD, Abramowitz J, Zhu MX, Bimbauer L (2009) A role for Orai in TRPC-mediated Ca2+ entry suggests that a TRPC-Orai complex may mediate store and receptor operated Ca2+ entry. Proc Natl Acad Sci U S A 106: 3202–3206. doi: 10.1073/pnas.0813346106 PMID: 19221033

28. Authi KS (2007) TRP channels in platelet function. Handb Exp Pharmacol: 425–443.

29. Varga-Szabo D, Authi KS, Braun A, Bender M, Ambily A, Hassock SR, et al. (2008) Store-operated Ca (2+) entry in platelets occurs independently of transient receptor potential (TRP) C1. Pflugers Arch 457: 377–387. doi: 10.1007/s00424-008-0351-4 PMID: 18546016
30. Carter RN, Tolhurst G, Walmsley G, Vizuete-Forster M, Miller N, Mahaut-Smith MP (2006) Molecular and electrophysiological characterization of transient receptor potential ion channels in the primary murine megakaryocyte. J Physiol 576: 151–162. PMID: 16857711

31. Hassock SR, Zhu MX, Trost C, Flockerzi V, Authi KS (2002) Expression and role of TRPC proteins in human platelets: evidence that TRPC6 forms the store-independent calcium entry channel. Blood 100: 2801–2811. PMID: 12351388

32. Paez Espinosa EV, Murad JP, Ting HJ, Khasawneh FT (2012) Mouse transient receptor potential channel 6: role in hemostasis and thrombogenesis. Biochem Biophys Res Commun 417: 853–856. doi: 10.1016/j.bbrc.2011.12.058 PMID: 22206677

33. Karim ZA, Zhang J, Banerjee M, Chicka MC, Al Hawas R, Hamilton TR, et al. (2013) IkappaB kinase phosphorylation of SNAP-23 controls platelet secretion. Blood 121: 4567–4574. doi: 10.1182/blood-2012-11-470468 PMID: 23613522

34. Lin OA, Karim ZA, Vemana HP, Espinosa EV, Khasawneh FT (2014) The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. PLoS One 9: e87026. doi: 10.1371/journal.pone.0087026 PMID: 24463639

35. Grynkiewicz G, Poenie M, Tsien RY (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. The Journal of biological chemistry 260: 3440–3450. PMID: 3838314

36. Osdoit S, Rosa JP (2001) Fibrin clot retraction by human platelets correlates with alpha(IIb)beta(3) integrin-dependent protein tyrosine dephosphorylation. The Journal of biological chemistry 276: 6703–6710. PMID: 11084040

37. Murad JP, Espinosa EV, Ting HJ, Khasawneh FT (2012) The C-terminal segment of the second extracellular loop of the thromboxane A2 receptor plays an important role in platelet aggregation. Biochemical pharmacology 83: 88–96. doi: 10.1016/j.bcp.2011.10.002 PMID: 22008592

38. Kattelman EJ, Venton DL, Le Breton GC (1986) Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548). Thrombosis research 41: 471–481. PMID: 3008368

39. Murad JP, Espinosa EV, Ting HJ, McClure D, Khasawneh FT (2012) A novel antibody targeting the ligand binding domain of the thromboxane A2 receptor exhibits antithrombotic properties in vivo. Biochem Biophys Res Commun 421: 456–461. doi: 10.1016/j.bbrc.2012.04.011 PMID: 22503974

40. Du X, Ginsberg MH (1997) Integrin alphaIIb beta3 and platelet function. Thrombosis and haemostasis 78: 96–100. PMID: 9198135

41. Shattil SJ, Brass LF (1987) Induction of the fibrinogen receptor on human platelets by intracellular mediators. The Journal of biological chemistry 262: 992–1000. PMID: 3100533

42. Roedding AS, Li PP, Warsh JJ (2006) Characterization of the transient receptor potential channels mediating lysophosphatidic acid-stimulated calcium mobilization in B lymphoblasts. Life Sci 80: 89–97. PMID: 16979191

43. Huang JS, Dong L, Kozasa T, Le Breton GC (2007) Signaling through G(alpha)13 switch region I is essential for protease-activated receptor 1-mediated human platelet shape change, aggregation, and secretion. The Journal of biological chemistry 282: 10210–10222. PMID: 17298951

44. Dorsam RT, Kim S, Jin J, Kunapuli SP (2002) Coordinated signaling through both G(i) and thromboxane-mimetic U46619 in the porcine isolated ear artery: role of the ERK-MAP kinase signal transduction cascade. British journal of pharmacology 139: 156–162. PMID: 12746234

45. Bhattacharya B, Roberts RE (2003) Enhancement of alpha2-adrenoceptor-mediated vasoconstriction by the thromboxane-mimetic U46619 in the porcine isolated ear artery: role of the ERK-MAP kinase signal transduction cascade. British journal of pharmacology 139: 156–162. PMID: 12746234

46. Huang Z, Liu P, Zhu L, Li N, Hu H (2014) P2X1-initiated p38 signalling enhances thromboxane A2-induced platelet secretion and aggregation. Thrombosis and haemostasis 112: 142–150. doi: 10.1160/TH13-09-0726 PMID: 24633352

47. O’Brien KA, Stojanovic-Terro A, Hay N, Du X (2011) An important role for Akt3 in platelet activation and thrombosis. Blood 118: 4215–4223. doi: 10.1182/blood-2010-12-323204 PMID: 21821713
52. Ramanathan G, Gupta S, Thielmann I, Pleines I, Varga-Szabo D, May F, et al. (2012) Defective diacyl-glycerol-induced Ca2+ entry but normal agonist-induced activation responses in TRPC6-deficient mouse platelets. J Thromb Haemost 10: 419–429. doi: 10.1111/j.1538-7836.2011.04596.x PMID: 22176814

53. Almirza WH, Peters PH, van Zoelen EJ, Theuvenet AP (2012) Role of Trpc channels, Stim1 and Orai1 in PGF(2alpha)-induced calcium signaling in NRK fibroblasts. Cell Calcium 51: 12–21. doi: 10.1016/j.ceca.2011.10.001 PMID: 22050845